Instruction 1(b).

FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See	STATEMENT OF CHANG
obligations may continue. See	

**OMB APPROVAL** OMB Number: ES IN BENEFICIAL OWNERSHIP Estimated average burden

hours per response:

0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

								investment c								
Name and Address of Reporting Person*  Kumar Ramesh				2. Issuer Name and Ticker or Trading Symbol Onconova Therapeutics, Inc. [ ONTX ]						(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Kumar	Itamesii											X Directo	or		10% Ow	ner
(Last)	(Fi	irst)	(Middle)	3.	Date o	f Earliest	Trans	saction (Mont	n/Dav/Year)			X Officer below)	(give title		Other (spector)	pecify
C/O ONCONOVA THERAPEUTICS, INC.					09/25/2015							President and CEO				
375 PHE	ASANT RU	UN														
(Ctroot)				—   4.	If Ame	ndment, [	Date	of Original File	ed (Month/Da	ay/Year)	6. Ir Line	ndividual or .	Joint/Group	Filing (	(Check App	licable
(Street) NEWTO	WN PA	A	18940									X Form f	iled by One	Report	ting Person	
												Form f Persor	iled by More า	than (	One Report	ing
(City)	(S	tate)	(Zip)													
		Tab	le I - Non-D	erivativ	e Se	curities	s Ac	quired, Di	sposed o	of, or Be	neficiall	y Owned	l			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)				e	Execution Date		Code (Instr.   5)			Beneficia Owned F	es Form ally (D) of Following (I) (II		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
							Code V	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	tion(s)			(Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	y [	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (right to purchase)	\$1.48	09/25/2015		A		87,500		(1)	09/25/2025	Common Stock	87,500	\$0	87,500		D	

## **Explanation of Responses:**

1. These options vest over four years in 48 equal monthly installments.

/s/ Ajay Bansal as attorney-infact

10/01/2015

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.